Neoadjuvant Immunochemotherapy for Lung Cancer

Fudan University

Status: Completed

Conditions: Lung Cancer

Treatments: Drug: Neoadjuvant immunochemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06023797

ZS-chest

Details and patient eligibility

About

We retrospectively analyzed lung cancer patients who had NAICT and surgery in the Department of Thoracic Surgery, Zhongshan Hospital. NAICT was defined as chemotherapy that included at one application of PD-1 inhibitor.

Enrollment: 83 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Lung surgery was performed in the Department of Thoracic Surgery at Zhongshan Hospital;
2. At least one cycle of neoadjuvant treatment containing the immune drug PD-1 immunosuppressant was performed before surgery;
3. Malignancy was present and confirmed in the pathology before treatment and after surgery;
4. The lung lesion was the primary lesion.

Exclusion criteria

1. No lung surgery was performed until 2022.11;
2. No preoperative neoadjuvant therapy was performed or recorded;
3. Neoadjuvant therapy did not include immune drugs;
4. Previous history of malignancy (including surgery and adjuvant therapy);
5. Previous use of system-related immune medicines, such as immunosuppressants and monoclonal antibodies; and 6. Other conditions inappropriate for enrollment by the investigator.

Trial design

83 participants in 1 patient group

MAICT

Description:

chemotherapy that included at one application of PD-1 inhibitor

Treatment:

Drug: Neoadjuvant immunochemotherapy